New pill could replace needles for anemia in dialysis patients
NCT ID NCT07494409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an oral drug called AND017 for anemia in people on dialysis due to end-stage kidney disease. About 300 participants will receive either AND017 capsules or a standard injected ESA. The goal is to see if AND017 can maintain healthy hemoglobin levels as well as or better than current treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AND017 capsules
- What this could lead to
- If successful, AND017 could offer a new oral option to manage anemia in dialysis patients, potentially reducing the need for injections.
- What could go wrong
- This is still an early Phase 3 trial with 300 participants. The drug may not prove better than existing treatments, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA DUE TO CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan Univeristy Zhongshan Hospital
RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new drug combo may shield kidney transplant patients from a common viral threat
- Could delaying kidney implant during heart transplant reduce complications?
- Dialysis duel: does higher fluid volume or lower sodium improve patient outcomes?
- Could an arthritis drug stop a deadly skin condition?
- New ultrasound technique spots hidden heart trouble in kids on dialysis
- Dialysis showdown: which blood thinner works best?